FDA Ticks Extra Patent Time for ADBRY Drug
Published Date: 5/14/2025
Notice
Summary
The FDA has officially set the review period for ADBRY, a human biological product, so its patent can be extended. This helps the company get extra time to protect their invention after the long approval process. If you’re involved in biotech or patents, this means the clock just got a little longer for ADBRY’s patent rights!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in